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     Helicobacter Pylori is the main cause of gastric ulcer, adenocarcinoma and mucosa-associated lymphoid 
tissue (MALT) lymphoma. Up to now, different regimens have been used for Helicobacter pylori (H.pylori) 
eradication to find the most potent and cost-effective regimen with less side effects. The aim of this study 
was to investigate the efficacy of standard triple therapy versus quadruple therapy for eradication of H. 
pylori. In a randomized clinical trial, 110 patients with H.pylori infection were randomly assigned into two 
groups of triple or quadruple therapy. The first group received standard triple therapy regimen with 
clarithromycin, amoxicillin and omeprazole and the second group received bismuth-based quadruple therapy 
regimen. At the end of study, stool antigen assay was used to confirm H.pylori eradication. 
The mean age of patients was 41.58 ± 11.98 years and 50.9% of them were male. Side effects of treatment 
with triple therapy were observed in 49.1% of cases. H.pylori eradication rate with triple and quadruple 
therapy regimen was 54.5% and 72.7% respectively but the difference was not statistically significant. 
Results showed that the efficacy of triple therapy was comparable to that of bismuth-based quadruple 
therapy regimen. However, due to the better compliance of triple therapy regimen, it is recommended for the 
first line treatment. Quadruple therapy could be used as an alternative treatment when triple therapy fails.  
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INTRODUCTION 
     The rate of Helicobacter pylori (H. pylori) 
colonization in the stomach in the United States 
and developed countries is about 20% and in most 
of developing countries is more than 80% in the 
adult population. The prevalence of H.pylori 
infection in the USA is age related. About 50% of 
individuals around 60 years old are infected, and 
25% of people in the age of 30 are H.pylori 
positive [1, 2]. Very low incidence of H.pylori 
among children in developed countries is due to 
the high life standards and increased use of 
antibiotics [1, 2]. H. pylori is the main inducer of 
chronic gastritis, gastric and duodenal ulcers, 
mucosa-associated lymphoid tissue (MALT) 
lymphoma and gastric cancer; so the treatment of 
H. pylori infection is very important. In the past 
20 years, the standard triple-drug regimen (PPI 
amoxicillin, clarithromycin, metronidazole) has 
been used widely in many countries as the first 
line treatment (Maastricht I, II)[3]. However, the 
standard triple-therapy regimen has certain 
limitations, just like other available antibiotics. 
Because of the side effects, patient compliance is 
reduced and drug resistance has increased [4, 5]. 
In recent years, a progressive decrease has been 
observed in the eradication rate of H. pylori 
because of resistant to clarithromycin and 
metronidazole [6, 7].  The efficacy of double, 
triple and quadruple regimens have been shown in 
73 clinical trials that revealed an H.pylori 
eradication rate of 61 to 93%. The reason for this 
low rate of eradication is not clear, but it seems 
that it is related to antibiotic resistances [8].  
Sasaki et al. evaluated the H.pylori resistance and 
eradication rate from 1995 to 2008. They 
determined the increasing rate of resistance from 
8.7% to 54.5% and reducing rate of eradication 
from 90.6% to 74.8% [9] .  
Now, considering the relationship between 
H.pylori infection and gastric cancer, using drug 
regimens that are effective in reducing the 
 




prevalence of H.pylori infection is necessary [9]. 
Up to now, different regimens have been used 
H.pylori eradication to find the most potent and 
cost-effective regimen with less side effects. 
This study aim was to investigate the efficacy of 
standard triple therapy regimen versus quadruple-
drug therapy for eradication of H. pylori infection 
in Iranian patients. 
 
MATERIALS AND METHODS 
     This randomized clinical trial was conducted 
in Modarres Hospital, Tehran, Iran during 2011-
2012. The study was conducted according to the 
principles of Helsinki deceleration and ethics 
committee at Shahid Behehsti University of 
Medical Sciences approved the study protocol. 
All patients signed written informed consent form 
before enrollment. 
Patients with dyspepsia, aged between 18 and 60 
years with positive UBT or serology test, and 
patients with dyspepsia older than 45 years who 
underwent endoscopy were included in the study. 
Patients with acute complications of peptic ulcer 
disease such as bleeding, obstruction, those aged 
more than 60 or less than 18, those took the same 
antibiotic during the last four weeks and those 
with allergic reaction to drugs and non-
compliance with drug regimen were excluded 
from the study.  
Patients with dyspepsia were selected randomly 
among the patients who referred to the 
gastroenterology clinic of Modarres hospital. 
They were examined for H. pylori infection with 
serology test or endoscopy (if necessary) or Urea 
Breath Test (UBT) or biopsy.  
The patients with positive H.pylori infection were 
divided randomly into two groups of 55 
individuals. Then the patients were treated 
separately with triple or quadruple drugs regimens 
for 14 days. Four weeks after completion of 
therapy, the eradication of H. pylori was 
evaluated by fecal antigen test. Stool-based test 
(SAA) was performed by ELISA II method. 
One group received standard triple therapy 
regimen with omeprazole (20mg b.i.d), 
amoxicillin (1 gr b.i.d) and clarithromycin (500 
mg b.i.d) for 14 days. The other group received 
bismuth-based quadruple therapy regimen with 
omeprazole (20mg b.i.d), bismuth (one tablet 
b.i.d), metronidazole (250mg q.i.d) and 
tetracycline (500mg q.i.d) for 14 days.  
Previous studies have shown that H.pylori 
eradication by triple therapy (clarithromycin, 
amoxicillin, omeprazole) is about 60% (4) and 
about 25% by quadruple regimens (bismuth, 
tetracycline, metronidazole, omeprazole). 
Statistical Analysis 
Statistical analyses were done using SPSS 
software ver.17.00 for Windows. To describe the 
data, mean, standard deviation, frequency and 
percentage were reported. For comparison of 
categorical data between the two groups, chi-
square and Fisher's exact tests were used. 
Independent sample t-test was used to compare 
numerical data with normal distribution between 
the two groups. P value less than 0.05 was 
considered significant.  
 
RESULTS 
     In this study, at first 146 patients were 
included in the study but 34 patients (23.6%) lost- 
to- follow-up in the next study steps, which 21 
(27.6%) of them were in quadruple therapy 
regimen and 13 (19.1%) were in triple therapy 
regimen (p>0.05) (Figure 1). 
 
Table 1: Demographic and clinical information of two study groups 
NS: non significant 
 
Variable Triple therapy group Quadruple therapy group All patients P value 
n 55 55 110  
Gender, n 30F, 25 M 24 F, 31M 54F, 56M NS 
Age, year, (mean ±SD) 41.38±11.41 41.78 ±12.6 41.58 ± 11.98 NS 
Methods of H.pylori diagnosis  
Urea Breath Test, n(%) 47 (85.5) 50 (90.9) 97 (88.2) NS 
Serologic Test, n(%) 5 (9.1) 2 (3.6) 7 (6.4) NS 
Biopsy and Histology, n(%) 3 (5.5) 3 (5.5) 6 (5.5) NS 
 





Figure 1. number of drop out in each study group 
 
Finally, 110 patients in two groups of 55 individuals 
completed the study and performed follow-up test 
with fecal Antigen test. The mean age of patients 
was 41.58 ± 11.98 years (ranged 18-60) and 49.1% 
of patients were female. Demographic information 
of two study groups has been shown in Table 1. 
There was no significant difference between the two 
groups regarding age and gender (p>0.05). 
 







NS: non significant 
 
Table 3. Treatment side effects in two study groups 
NS: non significant 
 
H.pylori infection was detected by different methods 
in our patients. Methods of H.pylori infection 
diagnosis in both study groups has been shown in 
Table 1. There was no significant difference 
between the two groups regarding the method of 
H.pylori infection diagnosis (p>0.05). Results of 
endoscopic examination in two study groups have 
been demonstrated in Table 2. There was no 
significant difference between the two groups 
regarding endoscopic findings (p>0.05). Overall, 
Finding Triple therapy group Quadruple therapy group All patients P value 
Normal, n(%) 24 (43.6) 23 (41.8) 47 (42.7) NS 
Erosive gastritis, n(%) 16 (29.1) 18 (32.7) 34 (30.9) NS 
Gastric ulcer, n(%) 6 (10.9) 4 (7.3) 10 (9.1) NS 
Duodenal ulcer, n(%) 9 (16.4) 10 (18.2) 19 (17.3) NS 
Side Effect Triple therapy group Quadruple therapy group All patients P value 
Abdominal distention, n(%) 12 (21.8) 6 (10.9) 18 (16.4) NS 
Abdominal pain, n(%) 4 (7.3) 12 (21.8) 16 (14.5) NS 
Constipation, n(%) 6 (10.9) 8 (14.5) 14 (12.7) NS 
Nausea and vomiting , n(%) 4 (7.3) 7 (12.7) 11 (10.0) NS 
Decreased  appetite, n(%) 5 (9.1) 4 (7.3) 9 (8.2) NS 
Impaired sense of taste, n(%) 4 (7.3) 5 (9.1) 9 (8.2) NS 
Coetaneous rash, n(%) 5 (9.1) 2 (3,6) 7 (6.4) NS 
Diarrhea, n(%) 5 (9.1) 1 (1.8) 6 (5.5) NS 
Total, n(%) 27 (49.1) 25 (45.5) 52 (47.3) NS 
 




complet H.pylori eradication was found in 70 
patients (63.6%) based on stool-based test (SAA). 
Although, H.pylori eradication rate in quadruple 
therapy group was higher than the triple therapy 
group but this difference was not statistically 
significant (72.7% vs. 54.5%) (p: 0.27). The 
compliance with the treatment in quadruple therapy 
group (27.6%) was numerically more than triple 
therapy group (19.1%) but the difference was not 
statistically significant (p>0.05). Side effects of two 
treatment regimens have been reported in Table 3. 
No significant difference was found between the 




    This study showed equal efficacy of standard 
triple and quadruple therapy regimens in H.pylori 
eradication. H. pylori is a gram-negative bacterium 
that has been colonized normally in human’s body. 
Human is the only reservoir of H. pylori. Children 
either receive these bacteria from their parents 
(usually their mother) or other children. The fecal-
oral or oral-oral transmission is not clearly specified 
[1]. It is estimated that about half of the human 
population are infected with H. pylori. Perhaps 
H.pylori is the most prevalent infection that can 
cause several complications in human [10]. In an 
Iranian study, the prevalence of H. pylori infection 
in patients over 10 years old has been reported 
36.5% [11]. Patients ‘compliance with triple therapy 
and quadruple therapy has been reported between 
70% and 97%, respectively [12-15]. In our study, 
the compliance with treatment in triple and 
quadruple treatment groups was not significantly 
different. This was in line with the findings of 
previous studies [13]. The reason could be due to 
the side effects of drugs in quadruple regimen 
instead of triple therapy.  
The most prevalent complications of treatment in 
this study were abdominal bloating, abdominal 
pain and constipation. Moghaddam and colleagues 
reported similar results but abdominal pain was the 
most observable complaint in patients using 
quadruple therapy which was seen in quadruple 
therapy more than triple therapy group. In this 
study, the efficacy of two regimens was similar. 
Eradication rate of H.pylori by triple therapy 
regimen has been reported from 50% to 90.7% 
[9,13,16-19] while the eradication rate by 
quadruple therapy regimen has been reported 
35.9%-84.1% [12-14,19, 20]. There are no 
significant differences in the majority of published 
studies between the eradication rate of triple and 
quadruple regimens [12-15].  
There was only one study that had found a 
significantly higher eradication rate of triple 
therapy with omeprazole, clarithromycin and 
amoxicillinthat compared to quadruple therapy 
with omeprazole, amoxicillin, metronidazole and 
bismuth (90.7% vs. 84.1%, p= 0.0001) [19]. 
 
CONCLUSION 
    According to our findings, there is no significant 
difference between the triple therapy and 
quadruple therapy regimens in terms of eradication 
rate of H. pylori and the side effects (except for 
abdominal pain). Due to better patients’ 
compliance, triple therapy is recommended as eht 
first-line treatment for H.pylori eradication. 
Quadruple drug therapy could be useful in cases 
with resistance or treatment failure.  
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